It was today approved by the medicines regulator. But draft guidance by the UK’s drugs watchdog ruled the benefits of the drug ‘are too small to justify the costs’. It was today approved by the medicines regulator. But draft guidance by the UK’s drugs watchdog ruled the benefits of the drug ‘are too small to justify the costs’.
‘Miracle’ Alzheimer’s drug WON’T be offered on the NHS after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year
